These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31892925)

  • 21. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study.
    Zhang X; Yin J; Li H; Li S; Walley J; Zou G; Zhang Z; Wei X
    Trop Med Int Health; 2015 Nov; 20(11):1431-1437. PubMed ID: 26171742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Better to Die Than Take These Medicines": A Community-Based Qualitative Study on the Determinants of Treatment Loss-to-Follow-Up in Tuberculosis Patients in District Faridabad, Haryana, India.
    Khaitan A; Rai SK; Krishnan A; Gupta SK; Kant S; Khilnani GC
    Cureus; 2022 May; 14(5):e25030. PubMed ID: 35591891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.
    Suryawanshi SL; Shewade HD; Nagaraja SB; Nair SA; Parmar M
    Public Health Action; 2017 Jun; 7(2):116-122. PubMed ID: 28695084
    [No Abstract]   [Full Text] [Related]  

  • 27. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa.
    Hirasen K; Berhanu R; Evans D; Rosen S; Sanne I; Long L
    PLoS One; 2018; 13(10):e0205463. PubMed ID: 30300403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia.
    Soeroto AY; Nurhayati RD; Purwiga A; Lestari BW; Pratiwi C; Santoso P; Kulsum ID; Suryadinata H; Ferdian F
    PLoS One; 2022; 17(1):e0263304. PubMed ID: 35089981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiologically Confirmed Tuberculosis: Factors Associated with Pre-Treatment Loss to Follow-Up, and Time to Treatment Initiation.
    Mwansa-Kambafwile J; Maitshotlo B; Black A
    PLoS One; 2017; 12(1):e0168659. PubMed ID: 28068347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
    Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
    Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and Application of a Multidrug-Resistant Tuberculosis Case Management System - Yunnan Province, China, 2017-2020.
    Chen J; Ruan Y; Wang K; Li L; Yang Y; Yang R; Xu L
    China CDC Wkly; 2022 Sep; 4(38):855-861. PubMed ID: 36284689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update of drug-resistant tuberculosis treatment guidelines: A turning point.
    Vanino E; Granozzi B; Akkerman OW; Munoz-Torrico M; Palmieri F; Seaworth B; Tiberi S; Tadolini M
    Int J Infect Dis; 2023 May; 130 Suppl 1():S12-S15. PubMed ID: 36918080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Low detection rate and therapeutic success of tuberculosis in a prison in EcuadorBaixo recrutamento de pacientes e sucesso no tratamento da tuberculose em uma prisão do Equador].
    Chong F; Marín D; Pérez F
    Rev Panam Salud Publica; 2019; 43():e106. PubMed ID: 31908648
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.